Mario Balsa, Medical Oncology resident at Catalan Institute of Oncology, shared a post on X about a recent article by Yibo Dai et al. published in Nature:
“Why do some patients respond better to immunotherapy?
Nature: PPP2R1A mutations linked to improved outcomes with ICB! Across cancer types, PPP2R1A-mutant tumors show:
- Increased OS and PFS after ICB
- Increased IFN-γ signalling and T-cell infiltration
- Preclinical data: targeting PP2A boosts ICB and CAR-T efficacy
If a scaffold protein becomes a signal…biology tells where therapy should go next!”
Title: PPP2R1A mutations portend improved survival after cancer immunotherapy
Authors: Yibo Dai, Anne Knisely, Mitsutake Yano, Minghao Dang, Emily M. Hinchcliff, Sanghoon Lee, Annalyn Welp, Manoj Chelvanambi, Matthew Lastrapes, Heng Liu, Zhe Yuan, Chen Wang, Hao Nie, Stephanie Jean, Luis J. Montaner, Jiakai Hou, Ami Patel, Shrina Patel, Bryan Fellman, Ying Yuan, Baohua Sun, Renganayaki Krishna Pandurengan, Edwin Roger Parra Cuentas, Joseph Celestino, Yan Liu, Jinsong Liu, R. Tyler Hillman, Shannon N. Westin, Anil K. Sood, Pamela T. Soliman, Aaron Shafer, Larissa A. Meyer, David M. Gershenson, David Vining, Dhakshinamoorthy Ganeshan, Karen Lu, Jennifer A. Wargo, Weiyi Peng, Rugang Zhang, Linghua Wang, Amir A. Jazaeri
Read the Full Article on Nature
More posts featuring Mario Balsa.
